🚨 Don’t fall for the “50% risk reduction” trap. That’s just RRR dressing up like a superhero 🦸‍♂️ But sometimes… it’s just a sidekick. Let’s decode RRR, ARR & NNT—the trio every doctor should master 👇 👩‍⚕️ Imagine a new adjuvant drug in breast cancer. Trial says: 💥 “Recurrence dropped by 50%!” Everyone claps. But should you? 🎭 That’s the illusion of Relative Risk Reduction (RRR). Let’s dig deeper: Here’s the real story: 🧪 Out of 100 patients: 🔹 Control: 20 recurrences 🔹 Treatment: 10 recurrences 📊 RRR = (20 - 10) / 20 = 50% 🧨 Flashy. Impressive. BUT… 📊 ARR = 20% - 10% = 10% ✅ That’s the true benefit. 📊 NNT = 1 / 0.10 = 10 👉 So, you must treat 10 patients to prevent 1 recurrence. Not bad. But not magic either. 🎯 Moral? RRR is a marketing flex 💪 ARR is the truth serum 💉 NNT? That’s the bedside number you tell your patient 👩‍⚕️🧓 #OncoTwitter #MedTwitter @myesmo @esmo_open @ASCO @OncoAlert @EricTopol @Atul_Gawande @VPrasadMDMPH @PeterAttiaMD @IBDMD @edgarvlermamd

Statistics teachers: this thread is for you beautiful people. Tune in.